1. Scrip
  2. >>Drug Pricing

Dupixent Stopped at UK Gate For AD As EMA Agrees To Review It In Asthma

 
• By Sten Stovall

Dupixent has been initially rejected by NICE to treat eczema on cost grounds, but Sanofi remains hopeful of UK entry - and the biologic's overall promise.

SC1804_Medical Biz_621316742 _1200.jpg
Dupixent has EU market approval For Eczema, Seeks Asthma OK too • Source: Shutterstock

Although Sanofi and Regeneron Pharmaceuticals Inc..'s Dupixent (dupilumab) has been halted at the UK entry gate for use in eczema - despite having EU marketing approval for the condition - on the grounds it doesn't offer adequate value for money, the duo has responded calmly, noting that it's early days in the NICE assessment process.

The duo's relaxed tone was doubtless helped by news out the same day that the European Medicines Agency agreed to review a request for a new indication for the interleukin-4 and -13 inhibitor as a treatment for asthma, mirroring an FDA decision last

More from Drug Pricing

Novartis Doubles Down On Push For Higher Drug Prices In Europe

 
• By Jessica Merrill

CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Soriot Cautions Europe Amid More US Expansion

 
• By Kevin Grogan

The AstraZeneca CEO again calls for rich European countries to pay more for new drugs because "a model where the US funds innovation in our industry for the entire world doesn't work."

Sanofi Spends Big In US But Offers Crumbs Of Comfort For Europe

 
• By Kevin Grogan

CFO François Roger tells Scrip the French drugmaker is flexible geographically on making investments but its spend in the US has risen regardless of the threat of tariffs.

More from Scrip

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.